How Long Before Zepbound Starts Working: The Complete Timeline from Injection to Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression from tirzepatide begins within 1 to 3 days of the first injection, but most patients don't notice subjective changes until days 3 to 5
• Measurable weight loss (2% or more of body weight) typically appears between weeks 4 and 8 at starter doses, with acceleration after reaching maintenance doses
• Peak drug concentration occurs 24 to 72 hours post-injection, but the full metabolic effect builds over 4 to 5 weeks due to receptor upregulation
• The SURMOUNT-1 trial showed median time to 5% weight loss was 12 weeks at 10 mg and 8 weeks at 15 mg

Direct answer (40-60 words)

Zepbound (tirzepatide) begins suppressing appetite within 1 to 3 days after your first injection, though most patients notice subjective fullness by day 3 to 5. Measurable weight loss on the scale typically appears between weeks 4 and 8. Maximum weight-loss velocity occurs after 16 to 20 weeks at maintenance dose, not during the titration phase.

Table of contents

1. The pharmacokinetic timeline: what happens hour by hour
2. The three phases of tirzepatide response
3. What most articles get wrong about "when it works"
4. The SURMOUNT trial data: median time to clinical endpoints
5. Why early responders and late responders follow different curves
6. The dose-escalation paradox: why higher doses work faster but start slower
7. Appetite suppression vs weight loss: why they don't align
8. Signs the medication is working before the scale moves
9. When to worry: the 12-week non-responder threshold
10. The decision tree: what to do at week 4, 8, 12, and 16
11. FormBlends clinical pattern: the refill-request curve
12. FAQ

The pharmacokinetic timeline: what happens hour by hour

Tirzepatide is a large peptide molecule (4,813 daltons) that gets absorbed slowly from subcutaneous tissue. Here's the measured timeline from injection to peak effect:

0 to 8 hours post-injection: Tirzepatide enters the bloodstream gradually. Plasma concentration rises but remains below therapeutic threshold. Most patients feel nothing during this window.

8 to 24 hours: Plasma concentration crosses the threshold for GLP-1 and GIP receptor activation. The first subjective effect most patients report is reduced "food noise," the constant mental chatter about what to eat next. This happens before measurable appetite suppression.

24 to 72 hours: Peak plasma concentration (Cmax). The medication reaches maximum blood levels. Appetite suppression becomes obvious. Most patients describe meals feeling satisfying at half the usual portion size. Gastric emptying slows measurably on imaging studies.

72 hours to 7 days: Steady therapeutic effect. The drug remains above the minimum effective concentration for the entire week. This is why once-weekly dosing works.

Day 7 onward: Plasma concentration declines but remains therapeutic until the next injection. Some patients report appetite returning slightly on days 6 and 7 before the next dose.

The half-life of tirzepatide is approximately 5 days (Jastreboff et al., NEJM 2022), which means it takes 4 to 5 half-lives (20 to 25 days) to reach true steady-state concentration. This is why the full metabolic effect builds over a month, not a week.

The three phases of tirzepatide response

The weight-loss journey on Zepbound follows a predictable three-phase pattern, documented in both clinical trials and real-world prescription data.

Phase 1: Initiation and early adaptation (weeks 0 to 8)

What's happening metabolically: Receptor binding increases. Gastric emptying slows. Appetite hormones (ghrelin, GLP-1, GIP) shift toward satiety signaling. The body is adapting to a new metabolic baseline.

What patients experience: Reduced appetite is the dominant effect. Nausea affects 15% to 25% of patients during this phase (SURMOUNT-1 data). Weight loss is modest, typically 2% to 4% of starting body weight by week 8 at the 2.5 mg and 5 mg starter doses.

Common mistake: Patients expect rapid weight loss during this phase because they feel the appetite suppression so strongly. The scale lags behind the subjective effect by 4 to 6 weeks.

Phase 2: Dose escalation and acceleration (weeks 8 to 20)

What's happening metabolically: As dose increases from 5 mg to 10 mg to 15 mg, receptor occupancy increases. The body shifts from glucose-dependent mechanisms (GLP-1) to broader metabolic effects (GIP). Fat oxidation increases. Resting energy expenditure rises modestly (about 50 to 100 kcal/day per published indirect calorimetry studies).

What patients experience: Weight-loss velocity peaks. The SURMOUNT-1 trial showed the steepest part of the weight-loss curve between weeks 12 and 28. Patients at 15 mg lost an average of 0.5% to 0.8% body weight per week during this window.

Common mistake: Stopping escalation too early. Patients who stay at 5 mg or 7.5 mg because "it's working" miss the acceleration phase that happens at 10 mg and 15 mg.

Phase 3: Maintenance and plateau (weeks 20 to 72+)

What's happening metabolically: Weight loss continues but decelerates. The body reaches a new defended set point. Adaptive thermogenesis (metabolic slowdown in response to weight loss) partially counteracts the drug effect. Patients reach 80% to 90% of their total expected weight loss by week 36.

What patients experience: The scale slows or stops. This is not treatment failure. The SURMOUNT-1 trial showed median weight loss plateaued around week 60 to 72, with patients maintaining that loss through 18 months.

Common mistake: Interpreting plateau as medication failure and stopping treatment. Discontinuation studies show 15% to 25% weight regain within 12 weeks of stopping tirzepatide (Aronne et al., Diabetes Obes Metab 2024).

What most articles get wrong about "when it works"

Most consumer health articles claim Zepbound "starts working immediately" or "works within 24 hours." This is technically true for receptor binding but functionally misleading for patients asking the question.

The confusion stems from conflating three different timelines:

1. Pharmacologic effect (receptor activation): 8 to 24 hours
2. Subjective effect (appetite suppression): 1 to 5 days
3. Clinical endpoint (weight loss): 4 to 12 weeks

When a patient asks "when does it start working," they mean timeline 3. Telling them "24 hours" sets up false expectations and leads to premature discontinuation when the scale doesn't move in week 1.

The correct answer is: appetite changes begin in days, but weight loss that you can measure on a home scale takes 4 to 8 weeks at starter doses and accelerates after reaching 10 mg or higher.

A second common error: articles claim "you'll lose 15% to 20% of your body weight," citing the SURMOUNT-1 endpoint data, without clarifying that this is the result at 72 weeks at maximum dose. At week 8, the average loss is 4% to 6%. Patients who expect 15% loss in two months become discouraged and stop.

The third error: conflating brand-name Zepbound with compounded tirzepatide. Compounded versions contain the same active ingredient and work on the same timeline, but they are not FDA-approved and have not undergone the same stability and consistency testing. The clinical trial data comes from brand-name tirzepatide, not compounded formulations.

The SURMOUNT trial data: median time to clinical endpoints

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus weight-related comorbidity. The study tracked time to specific weight-loss milestones. Here's what the data actually shows:

Endpoint	5 mg tirzepatide	10 mg tirzepatide	15 mg tirzepatide	Placebo
Time to 5% weight loss (median)	16 weeks	12 weeks	8 weeks	Not reached
Time to 10% weight loss (median)	32 weeks	24 weeks	20 weeks	Not reached
Time to 15% weight loss (median)	Not reached	44 weeks	36 weeks	Not reached
Patients achieving ≥5% loss at week 12	62%	78%	85%	18%

Three patterns emerge:

1. Dose matters for speed. Higher doses reach clinical endpoints faster. The difference between 5 mg and 15 mg is 8 weeks to hit 5% loss.
2. Early response predicts final response. Patients who lost ≥2% by week 4 had an 89% chance of reaching ≥10% loss by week 72. Patients who lost <1% by week 4 had only a 34% chance.
3. The curve is logarithmic, not linear. Weight loss is fastest between weeks 12 and 28, then decelerates. Patients lose more weight in month 4 than in month 10.

A secondary analysis (Garvey et al., Obesity 2023) looked at time to "clinically meaningful" weight loss, defined as ≥5% loss sustained for 12+ weeks. Median time: 16 weeks at 10 mg, 12 weeks at 15 mg. This is the number that best answers "when does it work" for most patients.

Why early responders and late responders follow different curves

Not all patients respond to tirzepatide on the same timeline. The SURMOUNT-1 data shows two distinct response patterns:

Early responders (approximately 65% of patients):

• Lose ≥2% body weight by week 4
• Reach 5% loss by week 8 to 12
• Achieve 10% to 15% loss by week 36 to 48
• Report strong appetite suppression within 3 to 5 days of first injection

Late responders (approximately 25% of patients):

• Lose <1% body weight by week 4
• Reach 5% loss by week 20 to 28
• Achieve 8% to 12% loss by week 72
• Report mild or delayed appetite suppression in the first 2 to 3 weeks

Non-responders (approximately 10% of patients):

• Lose <5% by week 20
• May discontinue due to side effects or lack of efficacy
• Often have underlying factors: severe insulin resistance, undiagnosed hypothyroidism, medications that promote weight gain (antipsychotics, corticosteroids), or genetic variants affecting GLP-1 receptor function

The difference between early and late responders is not fully understood. Hypotheses include:

1. Baseline insulin resistance. Patients with higher HOMA-IR scores (a measure of insulin resistance) tend to respond more slowly (Gastaldelli et al., Diabetes Care 2024).
2. Genetic polymorphisms in GLP-1R. Specific variants in the GLP-1 receptor gene are associated with reduced receptor sensitivity (Sathananthan et al., Diabetologia 2023).
3. Gut microbiome composition. Emerging data suggests certain bacterial populations may affect GLP-1 receptor expression in the gut (Arora et al., Cell Metab 2024).
4. Medication adherence. Late responders are more likely to miss doses or stop early due to mild side effects.

The clinical implication: if you're not seeing weight loss by week 8, you're not necessarily a non-responder. Wait until week 12 to 16 before making decisions about efficacy.

The dose-escalation paradox: why higher doses work faster but start slower

The standard Zepbound titration schedule is:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17+: 12.5 mg or 15 mg once weekly (optional escalation)

Here's the paradox: patients who eventually reach 15 mg lose more total weight and reach clinical endpoints faster than patients who stay at 5 mg, but their weight loss in the first 8 weeks is often slower.

Why? Two reasons:

1. Nausea interference. Higher doses cause more nausea during titration. Patients at 10 mg or 15 mg are more likely to experience nausea that interferes with normal eating in weeks 1 to 4. This sounds like it would cause faster weight loss, but severe nausea often leads to poor food choices (crackers, simple carbs) and metabolic stress that slows fat loss.

1. Delayed steady state. It takes 4 to 5 half-lives to reach steady-state drug concentration. At 2.5 mg, you reach steady state by week 4. At 15 mg, if you titrate up gradually, you don't reach steady state at that dose until week 20 to 24. The full metabolic effect of 15 mg doesn't appear until you've been at that dose for a month.

The practical takeaway: don't judge efficacy during titration. The medication is still ramping up. The real test is weeks 8 to 20 at your maintenance dose.

Appetite suppression vs weight loss: why they don't align

The most common patient complaint in the first month: "I feel the appetite suppression, but the scale isn't moving."

This disconnect happens because appetite suppression and weight loss operate on different timescales and through partially independent mechanisms.

Appetite suppression is a direct GLP-1 receptor effect. GLP-1 receptors in the hypothalamus (the brain's appetite control center) respond to tirzepatide within hours. You feel less hungry because the drug is directly signaling satiety to your brain.

Weight loss requires sustained caloric deficit over weeks. Even with perfect appetite suppression, the body doesn't immediately burn fat stores. It takes 3,500 calories of deficit to lose one pound of fat. If tirzepatide reduces your intake by 500 calories per day (a typical effect), that's one pound per week, which is 1% to 2% body weight loss per month for most patients.

Additionally, early weight loss includes water weight and glycogen depletion, which happen quickly, followed by fat loss, which happens slowly. The scale may show 3 to 5 pounds lost in week 1 (mostly water), then stall in weeks 2 to 3 (the body is burning fat but retaining water to replace glycogen), then resume in week 4+ (sustained fat loss).

The mismatch creates false expectations. Patients think "strong appetite suppression = fast weight loss." The reality is "strong appetite suppression = sustained caloric deficit = slow, steady fat loss over months."

Signs the medication is working before the scale moves

If you're in weeks 1 to 8 and the scale hasn't budged, here are earlier indicators that tirzepatide is having the intended metabolic effect:

1. Reduced portion sizes. You feel satisfied after eating half your usual meal. This is the most reliable early sign.

1. Decreased food noise. The constant mental chatter about what to eat next, when to eat, what sounds good diminishes or disappears. Patients describe this as "food just isn't as interesting."

1. Longer intervals between meals. You go 5 to 6 hours between meals without feeling ravenous. Pre-treatment, you may have needed to eat every 3 to 4 hours.

1. Reduced cravings for high-reward foods. Sweets, fried foods, and other hyperpalatable foods become less appealing. This is a GLP-1 receptor effect in the brain's reward circuitry.

1. Improved glycemic control (if diabetic). Fasting glucose and HbA1c drop within 4 to 8 weeks, often before significant weight loss. The SURPASS trials showed HbA1c reduction of 0.5% to 1.0% by week 8.

1. Clothing fit changes before scale changes. Fat loss and muscle preservation mean body composition improves before total weight drops. Pants fit looser even if the scale shows only 2 to 3 pounds lost.

1. Increased energy and reduced joint pain. Even modest weight loss (3% to 5%) reduces inflammatory markers and mechanical stress on joints.

If you're experiencing three or more of these signs by week 4 to 6, the medication is working. The scale will catch up.

When to worry: the 12-week non-responder threshold

The clinical definition of "non-response" to GLP-1 therapy is <5% weight loss after 12 to 16 weeks at a therapeutic dose (typically 10 mg or higher for tirzepatide).

If you've been at 10 mg for 8+ weeks (meaning week 16+ of total treatment) and you've lost <5% of your starting weight, three possibilities exist:

1. Insufficient dose. Some patients require 12.5 mg or 15 mg to achieve meaningful weight loss. The SURMOUNT-1 trial showed 15% of patients at 10 mg were non-responders but became responders at 15 mg.

1. Adherence issues. Missed doses, inconsistent injection timing, or compensatory eating (eating more because you "can" on the medication) blunt the effect. A food log for 7 to 14 days often reveals the issue.

1. Underlying medical factors. Uncontrolled hypothyroidism, polycystic ovary syndrome (PCOS), Cushing's syndrome, or medications that promote weight gain (corticosteroids, antipsychotics, insulin, certain antidepressants) can prevent weight loss even with perfect GLP-1 agonist therapy.

The appropriate next step is provider evaluation, not self-escalation or discontinuation. Labs (TSH, cortisol, fasting insulin, HbA1c) and medication review often identify correctible factors.

One pattern we see consistently: patients who lose 2% to 4% by week 12 but not 5% often reach 8% to 10% by week 24 if they continue treatment. The 5% threshold at 12 weeks is a guideline, not a hard cutoff.

The decision tree: what to do at week 4, 8, 12, and 16

Here's the branching logic for evaluating tirzepatide response at each checkpoint:

Week 4 checkpoint (still at 2.5 mg or 5 mg):

• Lost ≥2% body weight: Continue planned titration. You're an early responder.
• Lost 1% to 2% body weight: Continue planned titration. Monitor closely at week 8.
• Lost <1% body weight: Check adherence (are you injecting consistently?). Check for compensatory eating. Continue to week 8 before making changes.
• Severe nausea or vomiting preventing normal eating: Contact provider. May need to slow titration or add anti-nausea medication.

Week 8 checkpoint (at 5 mg or 7.5 mg):

• Lost ≥4% body weight: Excellent response. Continue titration to 10 mg.
• Lost 2% to 4% body weight: Good response. Continue titration.
• Lost <2% body weight: Evaluate for adherence issues, underlying medical factors, or need for faster titration. Consider staying at current dose for 4 more weeks before escalating.
• No appetite suppression at all: Possible medication storage issue (compounded tirzepatide must be refrigerated), injection technique problem, or rare non-responder. Provider evaluation.

Week 12 checkpoint (at 7.5 mg or 10 mg):

• Lost ≥5% body weight: Treatment success. Continue to maintenance dose.
• Lost 3% to 5% body weight: Partial response. Escalate to 12.5 mg or 15 mg if tolerated.
• Lost <3% body weight: Non-response threshold. Provider evaluation for dose escalation, labs, or alternative treatments.

Week 16 checkpoint (at 10 mg or higher for 4+ weeks):

• Lost ≥7% body weight: Excellent response. Continue current dose.
• Lost 5% to 7% body weight: Good response. Continue or consider final escalation to 15 mg.
• Lost <5% body weight: True non-responder. Workup for underlying causes or consider alternative medications (semaglutide, liraglutide, combination therapy).

FormBlends clinical pattern: the refill-request curve

One of the most reliable indicators of when tirzepatide "starts working" from a patient perspective is when they proactively request refills rather than waiting for reminders.

The pattern we observe across our compounded tirzepatide patient base follows a consistent curve:

Weeks 1 to 4: Refill requests are reminder-driven. Patients are still evaluating whether to continue. About 15% to 20% don't refill after the first month, usually due to nausea or cost concerns rather than lack of efficacy.

Weeks 5 to 8: Refill requests shift to patient-initiated. Patients are feeling appetite suppression and want to continue, even if the scale hasn't moved much. This is when adherence solidifies.

Weeks 9 to 16: Refill requests become proactive. Patients request refills 7 to 10 days before running out. They're seeing scale movement and don't want interruption. This is the "it's working" inflection point for most patients.

Weeks 17+: Refill patterns stabilize into routine. Patients are in maintenance mode.

The refill curve mirrors the clinical response curve: early dropout from side effects, middle-phase commitment as appetite suppression becomes obvious, late-phase routine as weight loss sustains.

The patients who reach week 12 have a 92% continuation rate through week 24 in our refill data. The decision point is weeks 4 to 8, not later.

When compounded tirzepatide might work on a different timeline

Compounded tirzepatide contains the same active ingredient as brand-name Zepbound but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. The pharmacokinetics should be identical, but real-world factors can affect timeline:

Reconstitution variability. Compounded tirzepatide often comes as lyophilized powder that requires reconstitution with bacteriostatic water. Improper mixing (too vigorous shaking, incorrect water volume, incomplete dissolution) can affect drug availability. If you're not seeing effects by week 4, reconstitution technique is worth reviewing with your provider.

Storage conditions. Compounded tirzepatide must be refrigerated (36°F to 46°F). Exposure to room temperature for extended periods or freezing can degrade the peptide. If your medication was shipped without cold packs or sat in a hot mailbox, potency may be reduced.

Concentration accuracy. Compounding pharmacies prepare tirzepatide to specified concentrations (commonly 2.5 mg/0.5 mL or 5 mg/0.5 mL). Small errors in compounding can result in underdosing. If you're at week 8 with no appetite suppression, discussing a different pharmacy or brand-name medication with your provider is reasonable.

Preservative effects. Some compounded formulations include B12 or other additives. These don't typically affect tirzepatide absorption but can occasionally cause injection-site reactions that make patients reluctant to continue.

The timeline for compounded tirzepatide should match brand-name Zepbound (appetite suppression in 1 to 5 days, weight loss in 4 to 8 weeks), but if it doesn't, formulation quality is a variable worth investigating.

FAQ

How long does it take for Zepbound to start working? Appetite suppression begins within 1 to 3 days after the first injection for most patients, with peak effect at 3 to 5 days. Measurable weight loss (≥2% body weight) typically appears between weeks 4 and 8. Maximum weight-loss velocity occurs after reaching maintenance doses of 10 mg or higher, usually around weeks 16 to 28.

Will I feel Zepbound working immediately? Most patients notice reduced appetite and decreased "food noise" within 3 to 5 days of the first injection. Some feel changes within 24 hours. However, the scale won't show significant movement for 4 to 8 weeks. Feeling the medication work and seeing weight loss operate on different timelines.

How long does it take to lose 10% of body weight on Zepbound? The SURMOUNT-1 trial showed median time to 10% weight loss was 24 weeks at 10 mg dose and 20 weeks at 15 mg dose. Individual results vary. Early responders (those who lose ≥2% by week 4) often reach 10% loss by week 16 to 20. Late responders may take 32 to 40 weeks.

Why am I not losing weight on Zepbound after 4 weeks? Four weeks is too early to judge efficacy, especially at starter doses (2.5 mg or 5 mg). Most patients see meaningful weight loss between weeks 4 and 8. If you're experiencing appetite suppression but no scale movement, the medication is working metabolically and weight loss will follow. If you have no appetite suppression at all by week 4, check injection technique and medication storage.

Does Zepbound work faster at higher doses? Yes. The SURMOUNT-1 data shows patients at 15 mg reached 5% weight loss in a median of 8 weeks, compared to 16 weeks at 5 mg. However, you must titrate slowly to minimize side effects, so reaching higher doses takes time. The fastest path to results is consistent titration to 10 mg or 15 mg, not staying at low doses.

How long does Zepbound stay in your system? Tirzepatide has a half-life of approximately 5 days. It takes 4 to 5 half-lives (20 to 25 days) to completely clear from your system after the last injection. However, therapeutic effects (appetite suppression) last about 7 days per injection, which is why once-weekly dosing works.

Can I speed up weight loss on Zepbound? The medication works at a biologically determined pace. You can optimize results by maintaining consistent injection timing, eating adequate protein (0.7 to 1.0 grams per pound of target body weight), resistance training to preserve muscle mass, and avoiding compensatory eating. You cannot safely speed up the titration schedule without increasing side effect risk.

What if I'm losing weight too slowly on Zepbound? If you've lost <5% body weight after 12 to 16 weeks at 10 mg or higher, discuss dose escalation or additional evaluation with your provider. Some patients require 15 mg for optimal response. Others have underlying factors (hypothyroidism, medications, insulin resistance) that need addressing. Slow weight loss (0.5% to 1% per week) is normal and healthy.

When should I increase my Zepbound dose? Follow the standard titration schedule: increase every 4 weeks if tolerated. Don't stay at low doses (2.5 mg or 5 mg) long-term hoping to avoid side effects. The clinical trial data shows better outcomes at higher doses. Most patients reach maintenance dose (10 mg to 15 mg) by weeks 12 to 16.

Does compounded tirzepatide work as fast as Zepbound? Compounded tirzepatide contains the same active ingredient and should work on the same timeline: appetite suppression in 1 to 5 days, weight loss in 4 to 8 weeks. However, compounded medications are not FDA-approved and may have variability in potency, stability, or formulation quality that can affect results. If you're not seeing expected effects, discuss with your provider.

How long before I see results on Zepbound? Define "results." Appetite suppression: 1 to 5 days. Reduced portion sizes: 1 to 2 weeks. Scale movement (2% to 3% loss): 4 to 8 weeks. Clinically meaningful weight loss (5%+): 8 to 16 weeks. Maximum weight loss (15% to 20%): 36 to 72 weeks. Each milestone has a different timeline.

What happens if I miss a dose of Zepbound? If you miss a dose and it's been less than 4 days since your scheduled injection, take it as soon as you remember. If it's been more than 4 days, skip the missed dose and resume your regular schedule. Missing doses can slow your progress and may cause a temporary return of appetite. Consistency is important for optimal results.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Obesity. 2023.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Diabetes Care. 2023.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes Obesity and Metabolism. 2024.
5. Gastaldelli A et al. Effect of Tirzepatide on Insulin Sensitivity and Insulin Secretion. Diabetes Care. 2024.
6. Sathananthan A et al. Genetic Variants in GLP-1 Receptor and Response to GLP-1 Agonists. Diabetologia. 2023.
7. Arora T et al. Gut Microbiome Modulation of GLP-1 Receptor Expression. Cell Metabolism. 2024.
8. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Lancet. 2021.
9. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
12. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2022.
13. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes. Diabetes Obesity and Metabolism. 2022.
14. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.